Surveillance of Influenza and Other Respiratory Infections in the Netherlands: Winter 2016/2017
Total Page:16
File Type:pdf, Size:1020Kb
Annual report Surveillance of influenza and other respiratory infections in the Netherlands: winter 2016/2017 Annual report Surveillance of influenza and other respiratory infections in the Netherlands: winter 2016/2017 A.C. Teirlinck1 L. van Asten1 P.S. Brandsema1 F. Dijkstra1 G.A. Donker2 A.B. van Gageldonk-Lafeber1 M. Hooiveld1,2 M.M.A. de Lange1 S.D. Marbus1 A. Meijer3 W. van der Hoek1 1. Infectious Diseases, Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven 2. NIVEL (Netherlands institute for health services research), Utrecht 3. Infectious Disease Research, Diagnostics and Screening, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven Colophon RIVM report number: 2017-0096 DOI 10.21945/RIVM-2017-0096 Contact: Anne Teirlinck: [email protected] This investigation has been performed by order and for the account of the Ministry of Health, Welfare and Sport (VWS), within the framework of the project ‘Epidemiologie en surveillance van Respiratoire infecties’, project number V/150207/17/RI, and ‘Labfunctie Respiratoire Virologie’, project number V/150305/17/RE. Report prepared by: Centre for Infectious Disease Control, National Institute for Public Health and the Environment with contributions of: National Influenza Centre – Erasmus Medical Centre Netherlands institute for health services research (NIVEL) Statistics Netherlands (CBS) KNCV Tuberculosis Foundation Legionella Source Identification Unit (BEL) at Regional Public Health Laboratory Kennemerland Jeroen Bosch hospital Leiden University Medical Centre (LUMC) Paediatric intensive Care Units A publication by the National Institute for Public Health and the Environment (RIVM) P.O. Box 1 3720 BA Bilthoven The Netherlands www.rivm.nl/en All rights reserved © 2017 RIVM-CIb-EPI Parts of this publication may be reproduced, provided acknowledgement is given to: National Institute for Public Health and the Environment, along with the title and year of publication. 2 | Surveillance of influenza and other respiratory infections in the Netherlands: winter 2016/2017 Synopsis Surveillance of influenza and other respiratory infections in the Netherlands: Winter 2016/2017 During the 2016/2017 winter season, the influenza epidemic in the Netherlands lasted for 15 weeks. This was longer than the nine-week average duration of epidemics in the twenty previous seasons. Influenza subtype A(H3N2) was the dominant influenza virus throughout the season. In general, baseline natural immunity against A(H3N2) is relatively low among the elderly. Indeed, the number of patients older than 65 years, who visited a general practitioner (GP) for influenza-like symptoms, was higher than last year when influenza A(H1N1)pdm09 predominated. In nursing homes, the number of patients with influenza-like symptoms was also high. In total, an estimated 500,000 patients had symptomatic influenza in the period between the beginning of October 2016 and the end of May 2017 and 6,500 patients were admitted to hospital for influenza-related symptoms. During the epidemic, there were 7,500 more deaths than expected in this 15-week period. The effectiveness of the influenza vaccine against the A(H3N2) virus was 47 per cent. The circulating Dutch A(H3N2) viruses displayed a good to moderate match with the strain that was used in the 2016 vaccine. The WHO has recommended that the same strain be used for the trivalent vaccine for the 2017/2018 season in the northern hemisphere. The B component in the 2017 trivalent vaccine also remains the same as it was in 2016, but the A(H1N1)pdm09 component will be replaced with a more recent virus. The effectiveness of the vaccine varies every season because it is never known which influenza virus(es) will dominate in the next influenza season. Also, the circulating influenza viruses can evolve over time and deviate from the chosen vaccine viruses. There were more reports of the notifiable respiratory infectious diseases made in the 2016 calendar year than in previous years: tuberculosis (889 notifications), psittacosis (60 notifications) and legionellosis (454 notifications). The increase in legionellosis notifications may be associated with the warm, wet weather conditions in 2016. However, several geographic clusters were observed whose existence could not be explained by heavy rainfall or other weather conditions and for none of these clusters could the source of infection be found. The number of notifications for Q fever (14 notifications) is still decreasing. However, the notifiable infectious diseases that present as pneumonia are notoriously underreported because most cases of community-acquired pneumonia are managed in primary care without specific diagnostic laboratory tests being made. Keywords: respiratory infections, flu, influenza, RS-virus, pneumonia, Legionnaires’ disease, Legionella, parrot fever, psittacosis, Q fever, tuberculosis Surveillance of influenza and other respiratory infections in the Netherlands: winter 2016/2017 | 3 Publiekssamenvatting Surveillance van influenza en andere luchtweginfecties: winter 2016/2017 In de winter van 2016/2017 duurde de griepepidemie 15 weken. Dit is langer dan het gemiddelde van negen weken in de afgelopen 20 jaar. Tijdens de gehele epidemie is vooral influenzavirus van het type A(H3N2) aangetroffen, waartegen ouderen over het algemeen minder weerstand hebben. Het aantal patiënten boven de 65 jaar dat de huisarts bezocht met griepachtige klachten was dan ook iets hoger dan vorig jaar, toen vooral influenza A(H1N1)pdm09 circuleerde. Vooral in verpleeghuizen waren er veel patiënten met griepachtige klachten. In totaal zijn naar schatting tussen begin oktober 2016 en eind mei 2017 ongeveer 500 duizend mensen ziek geworden door een infectie met het griepvirus en zijn ruim 6500 mensen in het ziekenhuis opgenomen vanwege griep gerelateerde problemen. Gedurende de epidemie overleden 7500 meer mensen dan in die periode was verwacht. Gevaccineerden hadden een 47 procent verlaagd risico om griep te krijgen. Er was een redelijk tot goede match tussen het vaccin en het A(H3N2) virus dat dit jaar griep veroorzaakte. De Wereldgezondheidsorganisatie (WHO) heeft daarom geadviseerd om volgend jaar hetzelfde A(H3N2) vaccinvirus te gebruiken. Het B-virus in het griepvaccin van volgend jaar zal ook hetzelfde blijven, maar het vaccinvirus A(H1N1)pdm09 wordt wel door een recenter virus vervangen. De effectiviteit van het vaccin kan per seizoen sterk verschillen doordat nooit van tevoren bekend is welke virussen in het volgend seizoen overheersen. Ook kunnen deze virussen door de tijd heen evolueren en gaan afwijken van de gekozen vaccinvirussen. Van de meldingsplichtige luchtweginfectieziekten zijn in 2016 zowel tuberculose (889 meldingen) als psittacose (60 meldingen) en legionellose (454 meldingen) vaker gemeld dan voorgaande jaren. De stijging bij legionellose kan deels worden toegeschreven aan het warme en natte weer. Bij enkele plaatselijke verhogingen was dit niet het geval en kon ook geen besmettingsbron worden gevonden. Het aantal meldingen van Q-koorts (14) bleef dalen. Het aantal gemelde gevallen van Q-koorts, psittacose en legionellose is altijd een onderschatting van het werkelijke aantal. Bij longontsteking wordt namelijk niet vaak de oorzaak vastgesteld, omdat ofwel niet altijd getest wordt of de test geen zekere oorzaak oplevert. Kernwoorden: luchtweginfecties, griep, influenza, RS-virus, longontsteking, pneumonie, legionella, papegaaienziekte, psittacose, Q-koorts, tuberculose 4 | Surveillance of influenza and other respiratory infections in the Netherlands: winter 2016/2017 Influenza-like illness surveillance at a glance Figure 1 Percentage of specimens from patients with influenza-like illness positive for influenza virus, RSV, rhinovirus or enterovirus, taken by sentinel GPs, and ILI incidence with epidemic threshold during the 2016/2017 respiratory season (week 40 of 2016 through week 20 of 2017), displayed by week of sampling (Source: NIVEL Primary Care Database, NIC location RIVM). 100 1 14 23 90 12 80 19 22 48 26 70 45 35 6 10 5 40 7 2317 60 30 5141 9 8 30 2 50 19 5 6 40 11 9 13 30 4 9 % Positive ILI specimens 20 11 8 8 2 10 ILI incidence per 10,000 inhabitants 7 1 2 1 0 0 40 42 44 46 48 50 52 2 4 6 8 10 12 14 16 18 20 Week number RSV Influenza virus B (Victoria lineage) Rhinovirus Influenza virus A(H3N2) Influenza virus B (Yamagata lineage) ILI incidence Influenza virus A(H1N1)pdm09 Epidemic threshold Enterovirus Footnote: ILI = influenza-like illness; GP = general practitioner; RSV = respiratoir syncytial virus. The numbers above the bars are the total number of tested specimens. Surveillance of influenza and other respiratory infections in the Netherlands: winter 2016/2017 | 5 6 | Surveillance of influenza and other respiratory infections in the Netherlands: winter 2016/2017 Contents Chapter 1 Introduction 11 1.1 Aim and focus of this report 11 1.2 Collaborations: national and international 13 Chapter 2 Syndrome surveillance 15 2.1 Acute respiratory infection (ARI) and influenza-like illness (ILI) 15 2.1.1 Key points 15 2.1.2 Background 15 2.1.3 Epidemiological situation, season 2016/2017 16 2.1.4 Discussion 17 2.1.5 Tables and figures 17 2.2 Community-acquired pneumonia (CAP) 23 2.2.1 Key points 23 2.2.2 Background 23 2.2.3 Discussion 23 2.2.4 Figures 24 2.3 Severe acute respiratory infections (SARI) 27 2.3.1 Key points 27 2.3.2 Background 27 2.3.3 Epidemiological